290 related articles for article (PubMed ID: 6191388)
1. [Oral antidiabetic agents: recent aspects].
Keller U; Berger W
Schweiz Med Wochenschr; 1983 Apr; 113(17):645-50. PubMed ID: 6191388
[TBL] [Abstract][Full Text] [Related]
2. [Role of oral hypoglycemic agents in the therapeutic approach to diabetic obesity].
Albert J; Ekoé JM
Sem Hop; 1983 Sep; 59(29-30):2135-40. PubMed ID: 6312587
[TBL] [Abstract][Full Text] [Related]
3. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic agents.
Francisco GE
Prim Care; 1990 Sep; 17(3):499-519. PubMed ID: 2236334
[TBL] [Abstract][Full Text] [Related]
5. [Oral antidiabetic agents including glucosidase inhibitors].
Raptis S
Internist (Berl); 1987 Apr; 28(4):243-53. PubMed ID: 3298124
[No Abstract] [Full Text] [Related]
6. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
7. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
8. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Harrigan RA; Nathan MS; Beattie P
Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
[TBL] [Abstract][Full Text] [Related]
9. [Diabetes mellitus under 30 years of age. Results of 18 years experience with oral treatment (author's transl)].
Mirouze J; Cartry E
Diabete Metab; 1975 Jun; 1(2):113-8. PubMed ID: 1234068
[TBL] [Abstract][Full Text] [Related]
10. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
11. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
Prendergast BD
Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
13. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
14. [Long term efficacy and tolerance of antidiabetic treatments. New data].
Mirouze J
Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493
[No Abstract] [Full Text] [Related]
15. [Differential therapy using oral antidiabetics].
Mehnert H
Internist (Berl); 1971 Nov; 12(11):468-75. PubMed ID: 4943878
[No Abstract] [Full Text] [Related]
16. Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus.
Pontiroli AE; Alberetto M; Bertoletti A; Baio G; Pozza G
Horm Metab Res; 1984 Dec; 16 Suppl 1():167-70. PubMed ID: 6398258
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
Graham JP; Stam D
Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
19. Biguanides. Mode of action and role in the up-to-date treatment of diabetes mellitus.
Fövényi J
Ther Hung; 1971; 19(2):43-8. PubMed ID: 5172874
[No Abstract] [Full Text] [Related]
20. Sulfonylureas: background and development of the field.
Levine R
Diabetes Care; 1984; 7 Suppl 1():3-7. PubMed ID: 6376027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
